TY - JOUR
T1 - The pharmacokinetics of teicoplanin in varying degrees of renal function
AU - Lam, Y. W.Francis
AU - Kapusnik‐Uner, Joan E.
AU - Sachdeva, Meena
AU - Hackbarth, Corinne
AU - Gambertoglio, John G.
AU - Sande, Merle A.
PY - 1990/5
Y1 - 1990/5
N2 - The pharmacokinetics of teicoplanin, a new glycopeptide antibiotic with activity against aerobic gram‐positive bacteria, were characterized after intravenous administration of a single 3 mg/kg dose in five healthy volunteers and six patients with various degrees of stable renal insufficiency. Serum and urine samples were collected during a 15‐day period and drug concentrations were assayed microbiologically. The mean elimination half‐life of teicoplanin was 162.6 ± 69.8 hours in healthy volunteers and was prolonged with decreased renal function. The mean plasma and renal clearances of teicoplanin in healthy subjects were 11.4 ± 1.5 ml/min and 10.0 ± 1.0 ml/min, respectively. Both values decreased in patients with renal failure and correlated significantly with measured creatinine clearances (r2 = 0.938 and 0.884, respectively). A nomogram for dosage adjustment in patients with varying degrees of renal failure is presented. Clinical Pharmacology and Therapeutics (1990) 47, 655–661; doi:
AB - The pharmacokinetics of teicoplanin, a new glycopeptide antibiotic with activity against aerobic gram‐positive bacteria, were characterized after intravenous administration of a single 3 mg/kg dose in five healthy volunteers and six patients with various degrees of stable renal insufficiency. Serum and urine samples were collected during a 15‐day period and drug concentrations were assayed microbiologically. The mean elimination half‐life of teicoplanin was 162.6 ± 69.8 hours in healthy volunteers and was prolonged with decreased renal function. The mean plasma and renal clearances of teicoplanin in healthy subjects were 11.4 ± 1.5 ml/min and 10.0 ± 1.0 ml/min, respectively. Both values decreased in patients with renal failure and correlated significantly with measured creatinine clearances (r2 = 0.938 and 0.884, respectively). A nomogram for dosage adjustment in patients with varying degrees of renal failure is presented. Clinical Pharmacology and Therapeutics (1990) 47, 655–661; doi:
UR - http://www.scopus.com/inward/record.url?scp=0025297391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025297391&partnerID=8YFLogxK
U2 - 10.1038/clpt.1990.87
DO - 10.1038/clpt.1990.87
M3 - Article
C2 - 2140543
AN - SCOPUS:0025297391
SN - 0009-9236
VL - 47
SP - 655
EP - 661
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 5
ER -